182 related articles for article (PubMed ID: 24596388)
1. Prolyl-isomerase Pin1 impairs trastuzumab sensitivity by up-regulating fatty acid synthase expression.
Yun HJ; Kim JY; Kim G; Choi HS
Anticancer Res; 2014 Mar; 34(3):1409-16. PubMed ID: 24596388
[TBL] [Abstract][Full Text] [Related]
2. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
3. Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability.
Lam PB; Burga LN; Wu BP; Hofstatter EW; Lu KP; Wulf GM
Mol Cancer; 2008 Dec; 7():91. PubMed ID: 19077306
[TBL] [Abstract][Full Text] [Related]
4. Stable suppression of tumorigenicity by Pin1-targeted RNA interference in prostate cancer.
Ryo A; Uemura H; Ishiguro H; Saitoh T; Yamaguchi A; Perrem K; Kubota Y; Lu KP; Aoki I
Clin Cancer Res; 2005 Oct; 11(20):7523-31. PubMed ID: 16243827
[TBL] [Abstract][Full Text] [Related]
5. The prolyl isomerase Pin1 enhances HER-2 expression and cellular transformation via its interaction with mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1.
Khanal P; Namgoong GM; Kang BS; Woo ER; Choi HS
Mol Cancer Ther; 2010 Mar; 9(3):606-16. PubMed ID: 20179161
[TBL] [Abstract][Full Text] [Related]
6. Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells.
Khanal P; Yun HJ; Lim SC; Ahn SG; Yoon HE; Kang KW; Hong R; Choi HS
Oncogene; 2012 Aug; 31(34):3845-56. PubMed ID: 22158035
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression.
Choi HJ; Kim JY; Lim SC; Kim G; Yun HJ; Choi HS
Br J Pharmacol; 2015 Nov; 172(21):5096-109. PubMed ID: 26267432
[TBL] [Abstract][Full Text] [Related]
8. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.
Menendez JA; Vellon L; Mehmi I; Oza BP; Ropero S; Colomer R; Lupu R
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10715-20. PubMed ID: 15235125
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
12. The prolyl isomerase Pin1 induces LC-3 expression and mediates tamoxifen resistance in breast cancer.
Namgoong GM; Khanal P; Cho HG; Lim SC; Oh YK; Kang BS; Shim JH; Yoo JC; Choi HS
J Biol Chem; 2010 Jul; 285(31):23829-41. PubMed ID: 20479004
[TBL] [Abstract][Full Text] [Related]
13. Prolyl isomerase PIN1 negatively regulates SGK1 stability to mediate tamoxifen resistance in breast cancer cells.
Jo A; Yun HJ; Kim JY; Lim SC; Choi HJ; Kang BS; Choi BY; Choi HS
Anticancer Res; 2015 Feb; 35(2):785-94. PubMed ID: 25667458
[TBL] [Abstract][Full Text] [Related]
14. Pin1 Inhibitor Juglone Exerts Anti-Oncogenic Effects on LNCaP and DU145 Cells despite the Patterns of Gene Regulation by Pin1 Differing between These Cell Lines.
Kanaoka R; Kushiyama A; Seno Y; Nakatsu Y; Matsunaga Y; Fukushima T; Tsuchiya Y; Sakoda H; Fujishiro M; Yamamotoya T; Kamata H; Matsubara A; Asano T
PLoS One; 2015; 10(6):e0127467. PubMed ID: 26039047
[TBL] [Abstract][Full Text] [Related]
15. Sensitizing effect of juglone is mediated by down regulation of Notch1 signaling pathway in trastuzumab-resistant SKBR3 cells.
Sajadimajd S; Yazdanparast R
Apoptosis; 2017 Jan; 22(1):135-144. PubMed ID: 27770268
[TBL] [Abstract][Full Text] [Related]
16. The prolyl isomerase Pin1 interacts with and downregulates the activity of AMPK leading to induction of tumorigenicity of hepatocarcinoma cells.
Khanal P; Kim G; Yun HJ; Cho HG; Choi HS
Mol Carcinog; 2013 Oct; 52(10):813-23. PubMed ID: 22549912
[TBL] [Abstract][Full Text] [Related]
17. The prolyl isomerase Pin1 interacts with a ribosomal protein S6 kinase to enhance insulin-induced AP-1 activity and cellular transformation.
Lee NY; Choi HK; Shim JH; Kang KW; Dong Z; Choi HS
Carcinogenesis; 2009 Apr; 30(4):671-81. PubMed ID: 19168580
[TBL] [Abstract][Full Text] [Related]
18. RNA-interference-mediated downregulation of Pin1 suppresses tumorigenicity of malignant melanoma A375 cells.
Jin J; Zhang Y; Li Y; Zhang H; Li H; Yuan X; Li X; Zhou W; Xu B; Zhang C; Zhang Z; Zhu L; Chen X
Neoplasma; 2013; 60(1):92-100. PubMed ID: 23067222
[TBL] [Abstract][Full Text] [Related]
19. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
20. Peptidyl prolyl isomerase, Pin1 is a potential target for enhancing the therapeutic efficacy of etoposide.
Mathur R; Chandna S; N Kapoor P; S Dwarakanath B
Curr Cancer Drug Targets; 2011 Mar; 11(3):380-92. PubMed ID: 21247380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
